| Project/Area Number |
26861300
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 尿路上皮癌 / 血管新生 / エピジェネティクス / 血管内皮細胞 / 血管新生阻害剤 / 上皮間葉転換 / メチル化 / バイオマーカー |
|---|
| Outline of Final Research Achievements |
We investigated the expression of vasohibin-1(VASH1) and vasohibin-2(VASH2) in urothelial carcinoma. VASH1 was especially expressed in the endothelial cells of the tumor stroma. Enhancer of zeste (EZH) 2, a methyltransferase and component of the polycomb repressive complex 2 (PRC2), plays an essential role in the epigenetic maintenance of the Histone H3 trimethyl Lys27 (H3K27me3) repressive chromatin mark. Because EZH2 associated the expression of vasohibin in the previous reports, we evaluated the immunohistochemical staining of EZH2, H3K27me3, and VASH1 in patients with urothelial carcinoma. EZH2 and H3K27me3 associated the grade of tumor, pathological T stage, and vasohibin-1 expression. These results suggested that the VASH1 associated with H3K27me3 and could be regulated by the epigenetic mechanism.
|
